A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

NCT05712174 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

176

Enrollment

OTHER

Sponsor class

Stopped Accrual to the biochemically recurrent and metastatic cohorts complete; however, accrual to the remaining two cohorts was lagging and deemed no longer feasible.

Conditions

Oncology
Prostate Cancer

Interventions

DRUG: [18]F-PSMA-1007

Sponsor

AHS Cancer Control Alberta